Sources: AstraZeneca, Bristol make bids for Amylin

Count AstraZeneca ($AZN) and Bristol-Myers Squibb ($BMY) among the bidders for diabetes drugmaker Amylin Pharmaceuticals ($AMLN), sources tell Reuters. Bristol got the bidding on Amylin started with a rebuffed offer earlier this spring, and AstraZeneca has been in the conversation about potential Amylin buyers in part because of the London-based drugmaker's acute need for new products and interest in the growing diabetes market. The two companies join Sanofi ($SNY) and Merck ($MRK) among initial bidders for Amylin, whose investors such as activist Carl Icahn would likely celebrate a bidding war among the Big Pharma groups. Article